Correlation of p27 protein expression with HER‐2/neu expression in breast cancer | Zendy

Newman Lisa | Zendy; Xia Weiya | Zendy; Yang HengYin | Zendy; Sahin Aysegal | Zendy; Bondy Melissa | Zendy; Lukmanji Farzana | Zendy; Hung MienChie | Zendy; Lee MongHong | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Correlation of p27 protein expression with HER‐2/neu expression in breast cancer

Author(s) -

Newman Lisa,

Xia Weiya,

Yang HengYin,

Sahin Aysegal,

Bondy Melissa,

Lukmanji Farzana,

Hung MienChie,

Lee MongHong

Publication year - 2001

Publication title -

molecular carcinogenesis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.254

H-Index - 97

eISSN - 1098-2744

pISSN - 0899-1987

DOI - 10.1002/mc.1025

Subject(s) - breast cancer , immunohistochemistry , biology , downregulation and upregulation , cancer research , oncology , cancer , medicine , correlation , protein expression , immunology , gene , biochemistry , genetics , geometry , mathematics

Strong expression of human epidermal growth factor receptor 2 (HER‐2)/neu in breast cancer has been associated with poor prognosis. Reduced expression of p27 Kip1 , a cyclin‐dependent kinase inhibitor, correlates with poor clinical outcome in breast cancer. In this study, we provide a correlation between these two important prognostic markers in patients with breast cancer. Breast tumor screening using immunohistochemistry indicated that downregulation of p27 correlated with HER‐2/neu overexpression in studying 11 normal breast tissues and 51 primary breast carcinomas. We found HER‐2/neu protein overexpression in 20 (41%) of 49 breast cancers and low p27 protein expression in 47 (92%) of 51 breast cancers. All 20 (100%) of the tumors that overexpressed HER‐2/neu had low levels of p27 protein product; this correlation was statistically significant ( P = 0.035). Decreasing p27 expression correlated with increasing HER‐2/neu activity. Our results suggest that one function of the HER‐2/neu product is to downregulate p27 expression in breast cancer. This study may be significant in selecting patients for HER‐2/neu antibody therapy in the future. Mol. Carcinog. 30:169–175, 2001. © 2001 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research